1. Andersson, S., Makitalo, B., Thorstensson, R., Franchini, G., Tartaglia, J., Limbach, K., Paoletti, E., Putkonen, P., and Biberfeld, G. (1996). Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis. 174: 977 - 985.
2. Barnett, S.W., Klinger, J.M., Doe, B., Walker, C.M., Hansen, L., Duliege, A.M., and Sinangil, F.M. (1998). Prime-boost immunization strategies against HIV. AIDS Res Hum Retroviruses 14 Suppl 3: S299 - S309.
3. Benenson, M.W., Sirisopana, N., Amphaipit, R., Tungsakul, V., Pumratana, K., Santativongchai, S., Nitayaphan, S., and Brown, A.E. (2001). Cohort development for future HIV-1 efficacy vaccine trials: a community cohort, Chon Buri Province, Thailand, In Sixth International Congress on AIDS in Asia and the Pacific, Melbourne, Australia. Berkley, S. (1999). An AIDS vaccine for all the world. Interview by Matthew O’Rourke. AIDS Clin Care 11: 55 - 57.
4. Berman, J. (1999). Thailand attacks AIDS with two-pronged approach. Lancet 353: 1600.
5. Birx, D.L., Brundage, J., Larson, K., Engler, R., Smith, L., Squire, E., Carpenter, G., Sullivan, M., Rhoads, J., Oster, C., James, W., Lupton, G., Wierzba, T., Burke, D., Redfield, R., and the Military Medical Consortium for Applied Retroviral Research. (1993). The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 6: 1248 - 1257.